Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153360 | 0.96 | CHEK1 (0.53) | CHEK1KCNH2FLT3HSP90AB1TOP2A | |
| SCHEMBL6156929 | 0.91 | MAPK14 (0.47) | CHEK1KCNH2FLT3HSP90AB1TOP2A | |
| SCHEMBL6154636 | 0.86 | TOP2A (0.46) | CHEK1KCNH2FLT3HSP90AB1TOP2A | |
| SCHEMBL6154711 | 0.83 | TOP2A (0.47) | HSP90AB1TOP2ARPS6KB1AURKA | |
| SCHEMBL6153232 | 0.78 | PTPN11 (0.44) | — | |
| SCHEMBL6153237 | 0.78 | PTPN11 (0.44) | — | |
| SCHEMBL6153233 | 0.78 | PTPN11 (0.44) | — | |
| SCHEMBL6154502 | 0.77 | ROCK2 (0.51) | CHEK1FLT3MAPKAPK2 | |
| SCHEMBL6154499 | 0.77 | ROCK2 (0.51) | CHEK1FLT3MAPKAPK2 | |
| SCHEMBL6154228 | 0.75 | FLT3 (0.54) | CHEK1KCNH2FLT3PDPK1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | CHEK1 2194/4885KCNH2 118/4885FLT3 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.